概括
胰岛素治疗可以纠正糖尿病大鼠的代谢问题. 然而,actinomycin D可以阻断胰岛素.
科学领域:
- 生物化学 生物化学
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 在老鼠中,阿洛克桑诱导的糖尿病会导致脂质和碳水化合物代谢的显著干扰.
- 胰岛素是调节葡萄糖和脂质平衡的关键激素.
研究的目的:
- 研究酶合成在胰岛素代谢作用中的作用.
- 为了确定是否需要RNA合成,以使胰岛素在糖尿病大鼠中的纠正作用.
主要方法:
- 在使用阿洛克桑的老鼠中诱导糖尿病.
- 胰岛素和actinomycin D (一种RNA合成抑制剂) 的使用.
- 测量脂肪酸和糖原合成中涉及的酶活性.
主要成果:
- 胰岛素治疗纠正了糖尿病大鼠的代谢障碍.
- 同时使用actinomycin D抑制了胰岛素修复脂肪酸和糖原合成中的酶性缺陷.
- 阿克丁诺米辛D没有影响胰岛素的低血糖作用.
结论:
- 胰岛素修复代谢缺陷的能力依赖于诱导酶合成.
- 这种诱导过程依赖于细胞RNA的更新.
- 胰岛素的基本机制包括刺激RNA更新以进行酶合成.
关键词:
在ACTINOMYCIN中使用.艾洛克森可以治疗糖尿病酶是一种酶.实验室研究实验室研究脂肪酸的代谢 脂肪酸的代谢胰岛素 胰岛素是一种肝脏 肝脏就是一个肝脏.肝脏的葡萄糖原体代谢过程中的代谢.药理学 在药理学方面.它们是老鼠.这是一个RNARNARNARNARNA.更多相关视频
08:01Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice
Published on: May 16, 2021
14:18Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
Published on: October 13, 2023
相关概念视频
Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
